Hematology Frontier

In March, as spring breathes new life into Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, organized by the Hematology and Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was successfully convened from March 27 to 28, 2026. During the meeting, Professor Zhenyu Yan from the Affiliated Hospital of North China University of Science and Technology delivered a keynote lecture entitled “Seven Transformations in the Comprehensive Diagnosis and Management of Hemophilia in China.”

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

Over the past 15 years, the field of hematopoietic stem cell transplantation has undergone a profound transformation, largely driven by breakthroughs in haploidentical transplantation. Represented by the “Beijing Protocol” pioneered by Professor Xiaojun Huang and his team at Peking University People’s Hospital, haploidentical transplantation has not only overcome the long-standing limitation of donor availability but has also achieved outstanding outcomes in the treatment of hematologic malignancies, leading to its widespread adoption worldwide.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. The congress gathered thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy, covering key topics such as optimization of transplant strategies, infection management, CAR-T therapy, and graft-versus-host disease (GVHD) management.

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential academic events in the field, the congress brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

he 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) marked a pivotal moment in prostate cancer research, featuring updates in disease classification, major clinical trial readouts, and evolving treatment paradigms.

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential international conferences in hematology, EBMT brings together experts worldwide to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapy.

Patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have an extremely poor prognosis. Historically, treatment options have been limited, and even with a second transplant, long-term survival has remained below 30%. There is therefore an urgent need for more effective therapeutic strategies.

At the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2026), held in Madrid, “Cell Therapy Day” emerged as one of the most prominent highlights of the congress. The session brought together leading experts from China, the United States, Germany, and other countries, who shared cutting-edge advances and forward-looking perspectives in cellular immunotherapy. The discussions reflected the rapid and diverse global evolution of this transformative field.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy. Key topics included optimization of transplant strategies, infection control, CAR-T therapy, and graft-versus-host disease management.